Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).
from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J
lecrab